Seattle Genetics, a biotech focused on development and commercialization of monoclonal antibody-based therapies for cancer and autoimmune disease, announced the appointment of Bruce Seeley as EVP, commercial. The company also announced the promotion of Kirk Schumacher to VP, legal affairs and compliance, and general counsel. Seeley was most recently a senior marketing director at Genentech, for Herceptin and T-DM1. Schumacher was most recently general counsel at Seattle Genetics.
Publicis Strategic Solutions Group named Christopher Dowd EVP, business development. In his new role, Dowd is responsible for leading business development activities, and reports to Rick Keefer, president and CEO. Dowd was most recently president of sales at Allergan.